RESUMO
OBJECTIVE: Minimally invasive techniques have been increasingly used to treat pathologic perforator veins (PVs). The goal of the present study was to summarize the current literature and determine the outcomes of treating PVs with or without the great saphenous vein/small saphenous vein using endovenous laser ablation (EVLA), radiofrequency ablation (RFA), and ultrasound-guided sclerotherapy (USGS). METHODS: A systematic review of the literature on the percutaneous treatment of PVs (35 studies) was conducted in accordance with the PRISMA (preferred reporting items for systematic reviews and meta-analyses) guidelines. Studies reported up to March 2020 were included. The incidence of several end points at different follow-up periods were calculated according to the availability of data within 3 to 12 months after the index procedure. RESULTS: Of the 35 studies, 15 (n = 1677) had reported on EVLA with or without sclerotherapy and/or microphlebectomy, 12 (n = 1477) had investigated the outcomes of RFA ablation with/without sclerotherapy, and 8 (n = 331) had investigated USGS alone. All techniques were safe in terms of periprocedural adverse events, with only a few complications occurring in each group. Immediate procedural success (within 30 days) was 95% in the EVLA group, 91% in the RFS group, and 58% to 70% in the USGS group. At 12 months of follow-up, the occlusion rates were 89%, 77%, and 83% in the EVLA, RFA, and USGS groups, respectively. The 12-month pooled estimate of ulcer healing between the EVLA and RFA groups was similar, although no direct comparisons were performed. CONCLUSIONS: Treatment of PVs with percutaneous techniques, such as EVLA, RFA, and USGS, is safe and associated with high technical success. EVLA and RFA exhibited the most favorable outcomes. Additional research is needed to validate these results, which were based on the limited level of evidence available to better determine the most optimal treatment approach for lower limb pathologic PVs.
Assuntos
Ablação por Cateter , Terapia a Laser , Varizes , Insuficiência Venosa , Ablação por Cateter/efeitos adversos , Ablação por Cateter/métodos , Humanos , Terapia a Laser/efeitos adversos , Terapia a Laser/métodos , Veia Safena/diagnóstico por imagem , Veia Safena/cirurgia , Escleroterapia/efeitos adversos , Escleroterapia/métodos , Resultado do Tratamento , Varizes/diagnóstico por imagem , Varizes/cirurgia , Insuficiência Venosa/diagnóstico por imagem , Insuficiência Venosa/etiologia , Insuficiência Venosa/terapiaRESUMO
INTRODUCTION: Treatment of cancer-associated venous thromboembolism (CAVTE) remains challenging. The aim of this study was to assess the outcomes of direct acting oral anticoagulants (DOAs) for the treatment of CAVTE. MATERIALS AND METHODS: A network meta-analysis of randomized clinical trials comparing DOAs (Apixaban, Rivaroxaban, and Edoxaban) versus Dalteparin for the treatment of CAVTE was performed. Outcomes of interest included, VTE recurrence, all-cause mortality, event-free survival, major bleeding, and clinically relevant non-major bleeding (CRNMB). Analysis was based on a random effects model and Bayesian Markov-chain Monte Carlo method was used for indirect comparisons. RESULTS: Four RCTs involving 2894 patients were included. Overall certainty of evidence was moderate regarding all outcomes. DOAs exhibited lower risk of VTE (RR 0.62; 95% CI 0.44, 0.87; P = 0.007), similar risk of major bleeding (RR 1.33; 95% CI 0.84, 2.11; P = 0.23), and higher risk of CRNMB (RR 1.66, 95% CI 1.08, 2.56; P = 0.02), compared with Dalteparin. Risk of all-cause mortality and event-free survival were similar between groups with RR 0.99 (95% CI 0.84, 1.16) and RR 1.03 (95% CI 0.94, 1.13), respectively. Apixaban ranked first for recurrent VTE (42.4%) and major bleeding (62.3%) and Dalteparin ranked first for CRNMB (54.7%). Rivaroxaban ranked best considering all-cause mortality (58.7%); Apixaban ranked best for event-free survival (83.6%). CONCLUSIONS: DOAs presented a reduced risk of recurrent VTE with similar risk of major bleeding compared to Dalteparin. However, a higher risk of CRNMB is expected when this cohort of patients are treated with DOAs instead of Dalteparin.
Assuntos
Neoplasias , Tromboembolia Venosa , Anticoagulantes/efeitos adversos , Teorema de Bayes , Inibidores do Fator Xa/efeitos adversos , Humanos , Neoplasias/complicações , Neoplasias/tratamento farmacológico , Metanálise em Rede , Tromboembolia Venosa/diagnóstico , Tromboembolia Venosa/tratamento farmacológico , Tromboembolia Venosa/etiologiaRESUMO
Ruptured thoracoabdominal aneurysms (rTAAAs) are rare and carry a significant rate of morbidity and mortality. Aortocaval fistula secondary to rTAAA is even more infrequent. We describe an urgent and staged endovascular treatment of a ruptured extent III thoracoabdominal aortic aneurysm with an aortocaval fistula by performing vena cava stenting to treat aortocaval fistula as a damage control maneuver prior to transfer and subsequent TAAA repair with a physician-modified endograft at a quaternary level hospital.